Lasmiditan clinical trials
Also written LY573144.
How each study uses lasmiditan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 11 Oct 2019 · REYVOW · NDA 211280 (FDA, Drugs@FDA)
- European Union
- 17 Aug 2022 · Rayvow · EMEA/H/C/005332 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2017 (12)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 12 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 32 · Other 0
Eli Lilly and Company (30) · IlDong Pharmaceutical Co Ltd (2)
Often tested with
Tested in the same studies.
Sumatriptan (2) · Rosuvastatin (1) · Propranolol (1) · Topiramate (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses lasmiditan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 32
- A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineTerminatedPhase 3Eli Lilly and CompanyNCT04396236Written as LasmiditanHow we know
- A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineTerminatedPhase 3Eli Lilly and CompanyNCT04396574Written as LasmiditanHow we know
- A Study of Lasmiditan in Healthy VolunteersCompletedPhase 1Eli Lilly and CompanyNCT04749914Written as LasmiditanHow we know
- A Study to Compare Two Different Formulations of Lasmiditan in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04881747Written as LasmiditanHow we know
- A Study of Lasmiditan (LY573144) Over Four Migraine AttacksCompletedPhase 3Eli Lilly and CompanyNCT03670810Written as LasmiditanHow we know
- A Study of Lasmiditan in Healthy Chinese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04081324Written as LasmiditanHow we know
- A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With MigraineCompletedPhase 2Eli Lilly and CompanyNCT03962738Written as LasmiditanHow we know
- Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in KoreanCompletedPhase 3IlDong Pharmaceutical Co LtdNCT04218162Written as Lasmiditan 50mgHow we know
- A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With MigraineCompletedPhase 1Eli Lilly and CompanyNCT03988088Written as LasmiditanHow we know
- An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of MigraineCompletedPhase 3Eli Lilly and CompanyNCT02565186Written as LasmiditanHow we know
- A Study of Lasmiditan on the Heart in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03465436Written as LasmiditanHow we know
- A Study of Lasmiditan on Simulated Driving Performance in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03459612Written as LasmiditanHow we know
- Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose AdministrationCompletedPhase 1Eli Lilly and CompanyNCT03040362Written as [14C]-lasmiditanHow we know
- A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug UsersCompletedPhase 1Eli Lilly and CompanyNCT03286218Written as LasmiditanHow we know
- The Effects of Lasmiditan on Simulated Driving Performance - Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03012334Written as LasmiditanHow we know
- A Study of Multiple Doses of Lasmiditan in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03252015Written as LasmiditanHow we know
- A Study of Lasmiditan in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03182920Written as LasmiditanHow we know
- Dose-ranging Study of Oral COL-144 in Acute Migraine TreatmentCompletedPhase 2Eli Lilly and CompanyNCT00883051Written as LasmiditanHow we know
- Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:CompletedPhase 3Eli Lilly and CompanyNCT02439320Written as Lasmiditan 100 mgHow we know
- A Study of Lasmiditan and Propranolol in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03270644Written as LasmiditanHow we know
Codes
What other systems call lasmiditan · ClinicalTrials.gg INT005761
- MeSH (NLM) C554777lasmiditanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 760I9WM792LASMIDITANConfirmed FDA, NLM, Wikidata
- RxNorm 2256930One source FDA
- Wikidata Q6493750lasmiditanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166996LasmiditanOne source FDA
- DrugBank DB11732One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C554777 | lasmiditan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 760I9WM792 | LASMIDITAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2256930 | — | One source FDA |
| Wikidata | Q6493750 | lasmiditan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166996 | Lasmiditan | One source FDA |
| DrugBank | DB11732 | — | One source Wikidata |
Also registered as lasmiditan succinate (UNII W64YBJ346B).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.